Zimbabwe has declined a significant American healthcare agreement valued at $367m (272 million pounds) spanning five years because of Washington's insistence on confidential data.
The decision became public after a official document dated December was leaked, revealing that Head of State Emmerson Mnangagwa deemed the agreement was "lopsided".
An official spokesperson later explained that the US was demanding access to health data for research and commercial purposes while refused to guarantee the resulting advantages from future treatments.
"We will now turn to the difficult and regrettable process of ending our support in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy said the United States had donated over $1.9bn for health programmes to Zimbabwe during the past twenty years.
A medical body in Zimbabwe has called for more negotiations to find a agreement acceptable to both sides so the nation's vital HIV programme can continue.
Broader Context
This development follows a comparable case in neighbouring Kenya, where a court halted a related deal with the US after concerns were raised about the security of citizens' medical information.
After returning to office last year, US President Donald Trump has reduced foreign aid and shut down the US Agency for International Development (USAID).
The agency had overseen aid for the US government, but Trump argued its spending was "wasteful" and his administration was seeking government-to-government agreements to enhance transparency and responsibility.
According to statements, 16 nations in Africa have to date agreed to similar agreements, representing over $18.3bn of fresh investment.
Details of the Declined Deal
The funds for Zimbabwe was intended to funded "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this cooperation could have provided significant benefits for Zimbabwean communities, particularly the 1.2 million currently on antiretroviral therapy via US-supported programmes," the Ambassador commented.
However, official spokesman Nick Mangwana maintained the arrangement was "unfair".
"Zimbabwe was being asked to share its genetic material and health information over an extended period, with no equivalent assurance of access to any medical innovations – like new medicines or tests – that might result from that shared data," Mangwana explained.
"In essence, our country would provide the basic resources for medical research with no assurance that the end products would be accessible to our citizens if a new pandemic emerge."
National Interest and International Frameworks
Mangwana further pointed out that the US's withdrawal from the global health body and its push of one-on-one health agreements were disrupting systems previously set up through the international organization.
The spokesperson gave as an example its Pandemic Benefit-Sharing scheme created to manage future pandemics.
"This system is designed to ensure that when a country contributes its information, the resulting advantages – such as vaccines and treatments – are shared equitably, not commercialised solely by those with the capability to develop them."
Zimbabwe's reservations over the US deal "are not meant as opposition to America," Mangwana stressed.
"We are open to continued dialogue with our American counterparts on how future collaboration might be structured in a way that respects the independence and interests of each country."
Medical Community Response
Medical experts said it recognised the government's concerns, but recommended that negotiations should continue since a large portion of the country's HIV programmes relied on foreign aid.
"Where technical issues arise, such as those relating to information security or implementation frameworks, these can often be resolved through technical clarification and mutually agreed protections," the group added.
The situation highlights the ongoing challenges between accepting vital international aid and safeguarding local interests in an ever more data-driven world.